Injectable antiplatelet therapies in acute coronary syndromes: Current status and Emerging Therapies. A position paper of the Task Force of Antithrombotic therapy of the ACVC. (PubMed, Eur Heart J Acute Cardiovasc Care) - Aug 22, 2026 - "Intravenous aspirin is used widely in patients with ACS, while the absorption of oral P2Y12 inhibitors is often delayed, and the intravenous P2Y12 inhibitor cangrelor can achieve almost complete platelet inhibition within minutes. While use of the glycoprotein IIb/IIIa inhibitors (GPI) eptifibatide and tirofiban is decreasing, typically reserved for thrombotic complications or no reflow following PCI, recently zalunfiban, a novel subcutaneously administered GPI has been shown to improve reperfusion before revascularisation in patients with STEMI when given at first medical contact. In this review, we dicuss the rationale and potential benefits of injectable antiplatelet medications, including currently available agents and those in development or being tested in clinical trials. While the benefit of injectable medications on hard clinical endpoints such as major adverse cardiac events remains unclear for an allcomers ACS population, there is emerging data that..."
Journal • Acute Coronary Syndrome • Anesthesia • Cardiovascular • Myocardial Infarction
|
|
Andrea Rubboli; Benedikt Schrage; Christoph B Olivier; Christophe Vandenbriele; Diana A Gorog; Diego Araiza-Garaygordobil; Konstantin A Krychtiuk; Kurt Huber; Mario Gramegna; Peter Clemmensen; Sogol Koolaji; Uwe Zeymer
|